News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. equities are outperforming China due to concentrated AI infrastructure investment.
  • U.S. industrial production is improving, supporting the market's momentum.
  • China's markets remain subdued because of a prolonged property downturn.
  • Potential U.S.-Iran sanctions relief could channel economic gains to the IRGC, raising compliance risk for international firms.
  • Porsche seeks to finalize a second round of employee cost cuts before July factory holidays amid profit pressure.
  • Analysts pitch Tantalus Systems as a discounted smart-grid growth stock after steady contract wins and rising software revenue potential.

Latest Articles

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

Spyre Therapeutics announced that SPY002, its anti-TL1A investigational antibody for moderate-to-severe ulcerative colitis (UC), met its primary endpoint in the Phase 2 SKYLINE trial Part A. The therapy demonstrated a significant reduction in Robart's Histopathology Index score by 10.7 points at Week 12, with notable clinical remission and endoscop…

Enphase Energy Appoints Shanker Trivedi to Board of Directors

Enphase Energy Appoints Shanker Trivedi to Board of Directors

Enphase Energy announced the appointment of Shanker Trivedi, former NVIDIA senior vice president of enterprise business, to its board of directors. Trivedi's expertise in AI, data centers, and enterprise infrastructure is expected to support Enphase's expansion in energy management, power conversion, and AI-driven energy infrastructure solutions. T…

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte announced positive Phase 3 trial results for its bioengineered acellular tissue engineered vessel (ATEV), which outperformed the standard autologous arteriovenous (AV) fistula for women on dialysis by extending catheter-free days and reducing infection rates. The trial showed women with ATEV avoided catheter use on average 3 months longer …

Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™  in Patients with Osteoarthritis

Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

Enlivex Ltd. announced the issuance of an Australian patent protecting the use of its immunotherapy Allocetra™ for treating osteoarthritis. This patent extends protection through at least 2040 and strengthens Enlivex's global intellectual property portfolio as it advances its Phase 2b clinical trials targeting moderate-to-severe age-related knee os…

Rectitude Holdings Ltd Secures Additional AIMS System Orders for Major Infrastructure and Residential Projects Across Singapore

Rectitude Holdings Ltd Secures Additional AIMS System Orders for Major Infrastructure and Residential Projects Across Singapore

Rectitude Holdings Ltd has secured additional orders for its flagship SuperSun All-in-One Intelligence Micro-Grid (AIMS) systems across multiple major public housing, private residential, and healthcare infrastructure projects in Singapore. The company has won a multi-site blanket order and a dedicated project engagement with Tanglin Corporation, p…

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

Grifols has launched FESILTY™, a new fibrinogen concentrate approved by the FDA in December for treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD). This product complements Grifols' bleeding management portfolio by providing a rapid, room-temperature stable, and precisely dosed treatment…

Byrna Technologies Realigns Sales and Marketing Function to Strengthen Brand Messaging and Accelerate Retail Expansion; Appoints HLK as Agency of Record

Byrna Technologies Realigns Sales and Marketing Function to Strengthen Brand Messaging and Accelerate Retail Expansion; Appoints HLK as Agency of Record

Byrna Technologies Inc. announced a strategic realignment of its sales and marketing functions, splitting the combined role into two dedicated senior leadership positions to sharpen retail sales and brand positioning efforts. The company appointed HLK as its agency of record to lead brand strategy, creative development, and media outreach, aiming t…

Oxford Lane Capital Corp. Provides May 2026 Net Asset Value Update

Oxford Lane Capital Corp. Provides May 2026 Net Asset Value Update

Oxford Lane Capital Corp. announced its unaudited net asset value (NAV) per share estimate for May 31, 2026, which is between $11.40 and $11.70. This preliminary estimate is subject to change and has not been approved by the board or undergone standard quarter-end procedures. The company highlighted potential impacts from market volatility on its p…

AFC Announces Dividend for the Second Quarter 2026

AFC Announces Dividend for the Second Quarter 2026

Advanced Flower Capital Inc. announced a quarterly dividend of $0.05 per share for the quarter ending June 30, 2026, payable on July 15, 2026. This dividend matches the payout from the prior quarter, reflecting steady dividend policy from the business development company which provides credit solutions to lower middle-market companies.

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 trials of navacaprant for major depressive disorder failed to meet primary and key secondary endpoints. The company will cease development of navacaprant and realign its resources to advance other pipeline programs in Alzheimer's disease agitation, schizophrenia, and cardiometabolic d…

Spielberg’s Disclosure Day opens to $93.9M worldwide in a surprise start

Spielberg’s Disclosure Day opens to $93.9M worldwide in a surprise start

Steven Spielberg's Disclosure Day opened to $93.9 million globally over the June 12-14 weekend, comfortably above pre-release forecasts. The film's strong debut - including a $44 million domestic opening from 3,824 theaters and $48.8 million internationally across 73 markets - provides a positive short-term data point for Comcast, which distributes…

Travel Stocks Rally After Tehran-Washington Accord, Oil Pulls Back

Travel Stocks Rally After Tehran-Washington Accord, Oil Pulls Back

Shares of major U.S. carriers and cruise operators jumped Monday after a preliminary agreement between Washington and Tehran to end the Iran war and reopen the Strait of Hormuz. The deal coincided with crude oil sliding more than 5% to its lowest level since March, easing fuel-cost worries that weigh on travel company margins.

Analysts Drive Datadog Rally as AI Demand and Upgrades Bolster Stock

Analysts Drive Datadog Rally as AI Demand and Upgrades Bolster Stock

Datadog shares jumped in pre-market trading after Truist Securities upgraded the stock to Buy and raised its price target to $300, citing strong fieldwork showing enterprise urgency around AI. BMO Capital also increased its target, and the company’s robust first-quarter 2026 results and updated guidance reinforced the bullish analyst momentum.